BIOSTAR NATURE CELL SELECTS ADDITIONAL U.S. CLINICAL CENTER FOR TRIALS OF ITS STEM CELL DRUG FOR ALZHEIMER’S DISEASE – ‘ASTROSTEM’
- Valden Medical Hospital in Hawaii is selected following the other two hospitals in California, U.S.
- Geographical proximity makes it easier to supply clinical drugs manufactured in South Korea
Biostar Stem Cell Research Institute, jointly managed by Biostar Nature Cell and Biostar R Bio, has officially announced the name of the third clinical center for the phases I and II clinical trials of ‘ASTROSTEM’, a stem cell drug for Alzheimer’s disease that is currently undergoing clinical trials following the approval from the U.S. Food and Drug Administration (FDA).
In addition to two other locations in California (ATP Clinic and Syrentis Clinic), where patients are currently being recruited, VALDEN MEDICAL HOSPITAL in Hawaii has been chosen as the third clinical center.
Hawaii presents the advantage of being geographically closer to South Korea than to California. Therefore, the supply of clinical drugs manufactured by South Korea’s Biostar Stem Cell Research Institute is expected to become a lot easier.
Through previous experimental trials involving animals ‘ASTROSTEM’ has shown its fundamental superiority to the conventional dementia drugs, which could only slow down the symptoms of dementia, while ‘ASTROSTEM’ could remove beta-amyloid – the principal cause of Alzheimer’s disease. If ‘ASTROSTEM’ is approved in the future, it is expected to enhance the treatment of the disease, and significantly improve the quality of life for millions of Alzheimer’s patients around the world.
“The phases I and II of clinical trials for Alzheimer’s disease patients in the U.S. will be completed by the end of next year as the hospital in Hawaii has been chosen in addition to the two existing hospitals in California.”, said Dr. Jeong-chan Ra, the Director of Research at Biostar Stem Cell Research Institute and the leading expert in the clinical trials on Alzheimer’s disease in the U.S. Dr. Ra also added, “We will apply for phase III conditional commercial clinical trial through the Korea Food and Drug Administration (KFDA) in the latter half of this year after confirming the safety and well-being of three patients in the initial clinical trial in the U.S. all the way up to the third injection.”